UNSPSC 51172326: Sodium edetate

This classification denotes a chelating agent with the molecular formula C10H12N2O8.4Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MP1J8420LU, chemically known as tetrasodium ethylenediamine-n,n,n,n-tetraacetate but generally known as edetate sodium, which bears US NIH Compound Identifier 6144. European Medicines Agency schedules Edetate sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB37153.

World Health Organization schedules edetate sodium in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule sodium edetate under HS 29224990 and SITC 51465. SMILES: [NA].[NA].[NA].[NA].OC(=O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O.

UNSPSC 51172326 Sodium edetate is a Commodity code that state and local governments procure as a component in drug-testing and pharmaceutical-supply operations. Recent solicitations show the code applied primarily in two contexts: as part of laboratory reagent and specimen-collection protocols within criminal justice drug-testing programs, and as a pharmaceutical input within multistate cooperative purchasing vehicles for generic and OTC pharmaceutical distribution. The issuing bodies span county criminal justice departments, state health and human services commissions, and multistate cooperative purchasing alliances administering pharmaceutical supply contracts for participating state and local government facilities.

Collin County, Texas posted the most concrete recent opportunity under this code: an RFP for Offender Specimen Collection and Drug Testing Services (RFP 2026-327, due July 23, 2026) with an estimated contract value of $600,000 over two years plus optional renewals, requiring specimen collection at two sites, immunoassay screening with LC/MS/MS or GC/MS confirmation, and alternative methodologies including oral fluid and hair testing for approximately 25,031 annual tests. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued a competing RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness and the remainder on pricing format compliance, EDI capability, and administrative requirements. Texas Health and Human Services Commission posted a Request for Information (RFI HHS0017013) in April 2026 gathering market intelligence on direct-to-manufacturer prescription programs as a preliminary phase before formal solicitation. Activity concentrates in Texas and the upper Midwest, with code application varying significantly between criminal justice testing procurement and pharmaceutical supply distribution.